Market Overview

Alpine Immune Sciences Strengthens Leadership Team with Appointment of Mark Litton as President and Chief Operating Officer

Share:

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a company focused on
discovering and developing innovative immunotherapies to treat cancer,
autoimmune/inflammatory and other diseases, today announced the
appointment of life sciences veteran Mark Litton, Ph.D. to the role of
President and Chief Operating Officer. Dr. Litton joins Alpine from
Alder BioPharmaceuticals, where he has served as Chief Business Officer
and Treasurer since co-founding the company in 2004.

"We are excited for Mark to take on this key leadership role during a
pivotal time for Alpine as we work to drive our two lead programs toward
the clinic," said Mitchell H. Gold, M.D., Executive Chairman and Chief
Executive Officer of Alpine. "Mark's deep experience in operating and
growing life science companies, as well as developing strategy and
executing transactions, will prove invaluable as we enter the clinic and
the next phase of development as a company. We believe we are on the
cusp of an exciting potential breakthrough in the next generation of
therapies for cancers and autoimmune/inflammatory diseases, and we are
committed to providing better treatment options for patients."

At Alder BioPharmaceuticals, Dr. Litton oversaw the company's business
operations, including playing an integral role in Alder's initial public
offering and subsequent financings, as well as high-profile
collaborations and partnerships. Prior to co-founding Alder
BioPharmaceuticals, Dr. Litton served as Vice President of Business
Development at Celltech Group, where he was responsible for securing,
commercializing, and partnering numerous novel discoveries and
therapeutic programs. He joined Celltech as part of Chiroscience Group
plc and was later named Vice President of Business Development upon
Chiroscience's merger with Celltech in 1999. Earlier, Dr. Litton served
as Manager of Business Development for Ribozyme Pharmaceuticals Inc.
(now Sirna Therapeutics, Inc.), where he played a key role in developing
the company's relationships with Eli Lilly and Company, Roche
Biosciences, and GlaxoWellcome plc (now GlaxoSmithKline plc). Prior to
that, Dr. Litton was a research associate at DNAX Research Institute, a
research facility of Schering-Plough (now Merck & Co.).

"Alpine is comprised of a group of talented and dedicated individuals,
working every day to discover and develop potential best-in-class,
next-generation therapies for patients," said Dr. Litton. "I am honored
to be joining the company at such an exciting time and am thrilled to be
working alongside Mitch and the entire Alpine team in driving our
strategy forward."

Dr. Litton holds a Ph.D. in Immunology from Stockholm University, an MBA
from Santa Clara University, and a B.S. in Biochemistry from the
University of California, Santa Cruz.

Jay Venkatesan, M.D., who previously served as President of Alpine
Immune Sciences, will continue to support Alpine Immune Sciences in his
Director role and will resume his primary role as a managing partner at
Alpine BioVentures.

About Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc. is focused on developing novel
protein-based immunotherapies using its proprietary Variant Ig Domain
(vIgD) technology. Alpine's proprietary scientific platform is designed
to interact with multiple targets, including many present in the immune
synapse. Alpine's vIgDs are developed using a process known as directed
evolution, which produces proteins capable of either enhancing or
diminishing an immune response and thereby may potentially apply
therapeutically to cancer, autoimmune/inflammatory and other diseases.
Alpine has also developed Transmembrane Immunomodulatory Protein (TIP)
technology, based on the vIgD technology, to potentially enhance
engineered cellular therapies. For more information, visit www.alpineimmunesciences.com.

Forward-Looking Statements

This release contains forward-looking statements within the meaning
of Section 27A of the Securities Act of 1933, Section 21E of the
Securities Exchange Act of 1934 and the Private Securities Litigation
Reform Act of 1995. These forward-looking statements are not based on
historical fact and include statements regarding Alpine's platform
technology, potential therapies, future development plans, clinical and
regulatory objectives and the timing thereof, and expectations regarding
the potential efficacy and commercial potential of Alpine's and its
collaborator's product candidates. Forward-looking statements generally
include statements that are predictive in nature and depend upon or
refer to future events or conditions, and include words such as "may,"
"will," "should," "would," "expect," "plan," "intend," and other similar
expressions among others. These forward-looking statements are based on
current assumptions involving risks, uncertainties, and other factors
that may cause actual results, events, or developments to be materially
different from those expressed or implied by such forward-looking
statements. These risks and uncertainties, many of which are beyond our
control, include, but are not limited to: Alpine's discovery-stage and
pre-clinical programs may not advance into the clinic or result in
approved products on a timely or cost-effective basis or at all; Alpine
may not achieve additional milestone payments pursuant to its
collaborations; the impact of competition; adverse conditions in the
general domestic and global economic markets; as well as the other risks
identified in our filings with the Securities and Exchange Commission.
These forward-looking statements speak only as of the date hereof,
Alpine undertakes no obligation to update forward-looking statements,
and readers are cautioned not to place undue reliance on such
forward-looking statements.

"Transmembrane Immunomodulatory Protein," "TIP," "Variant Ig Domain,"
"vIgD," and the Alpine logo are registered trademarks or trademarks of
Alpine Immune Sciences, Inc. in various jurisdictions. All other
trademarks belong to their respective owners.

View Comments and Join the Discussion!